Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing immune-oncology technologies to treat cancers. Its DNase technology targets neutrophil extracellular traps (NETS), which are involved in cancer growth, metastasis, and progression, and contribute to immunotherapy, chemotherapy, and radiotherapy resistance. The company's product pipeline includes XBIO-015 for the treatment of pancreatic carcinoma and solid tumors; XBIO-020 for the treatment of solid tumors; and ErepoXen, which uses PolyXen platform technology for the treatment of anemia in chronic kidney disease (CKD) patients. It has a sublicensing agreement with Takeda Pharmaceutical Co. Ltd, as well as various research, development, license and supply agreements with Serum Institute of India, PJSC Pharmsynthez, and SynBio, LLC. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.
Frequently asked questions
What sector does Xenetic Biosciences Inc (XBIO) operate in?
Xenetic Biosciences Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Xenetic Biosciences Inc (XBIO) current stock price?
As of the latest data, Xenetic Biosciences Inc stock price is $1.85, with a previous close of $1.72. Xenetic Biosciences Inc gained $0.13 in the last trading session, representing a 7.56% increase.
What is Xenetic Biosciences Inc (XBIO) current market capitalization?
Xenetic Biosciences Inc market cap is approximately 4.33 million.
What is Xenetic Biosciences Inc (XBIO) Earnings Per Share (EPS)?
The trailing EPS is -$1.15, and the forward EPS is -$0.34.
What is Xenetic Biosciences Inc (XBIO) EBITDA?
Xenetic Biosciences Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -929.70 thousand.
Does Xenetic Biosciences Inc (XBIO) pay dividends?
No. Xenetic Biosciences Inc does not pay a dividend.
When is Xenetic Biosciences Inc (XBIO) next earnings report?
Xenetic Biosciences Inc is expected to release its next earnings report on September 30, 2026.
What is Xenetic Biosciences Inc (XBIO) beta (volatility) score?
Xenetic Biosciences Inc has a beta of 2.202, indicating very high volatility compared to the market.
